Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has issued an announcement.
Chimeric Therapeutics Limited has notified the market of the issue of several classes of unquoted securities, including 4,666,683 options expiring on December 31, 2030 with a $0.50 exercise price and 500,000 options expiring on March 31, 2029 with a $0.60 exercise price. The company is also issuing 750 convertible notes, all dated April 29, 2026, as part of previously announced transactions, indicating continued use of structured, unquoted securities to fund its activities and potentially align incentives with longer-term performance.
These unquoted securities are not intended to be listed on the ASX, suggesting Chimeric is targeting specific investors or participants rather than broad public equity markets for this capital raise. The issuance structure may help the company manage dilution in its quoted share capital while still accessing funding and providing option-based incentives tied to future share price performance, which is relevant for existing shareholders monitoring potential future conversion and exercise impacts.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is a biotechnology company listed on the ASX under the code CHM. The company operates in the therapeutic sector, focusing on developing medical treatments, and raises capital through a mix of equity-linked instruments such as options and convertible notes to support its operations and growth initiatives.
Average Trading Volume: 219,607
Technical Sentiment Signal: Sell
Current Market Cap: A$8.84M
Learn more about CHM stock on TipRanks’ Stock Analysis page.